Zurcher Kantonalbank Zurich Cantonalbank Has $8.80 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 56.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 123,195 shares of the medical equipment provider’s stock after selling 158,918 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Hologic were worth $8,802,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic during the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC bought a new position in shares of Hologic in the third quarter valued at $29,000. NBC Securities Inc. bought a new position in shares of Hologic in the third quarter valued at $33,000. Bartlett & CO. Wealth Management LLC bought a new position in shares of Hologic in the fourth quarter valued at $33,000. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is currently owned by corporate insiders.

Hologic Trading Up 0.4 %

HOLX opened at $75.38 on Friday. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88. The company has a 50-day simple moving average of $75.75 and a 200 day simple moving average of $72.57. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $17.69 billion, a price-to-earnings ratio of 35.73, a P/E/G ratio of 2.54 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business’s quarterly revenue was down 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.07 earnings per share. Analysts predict that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Wednesday, April 10th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus price target of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.